NCT07172217View on ClinicalTrials.gov

The Efficacy and Safety RC48 Plus QL1706 in Second-Line Treatment of HER2-Expressing Recurrent CC

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

October 1, 2025

Primary Completion Date

February 28, 2027

Study Completion Date

December 31, 2028

Conditions
Recurrent Cervical Cancer
Interventions
DRUG

RC48

Disitamab Vedotin (RC48) : 2.5 mg/kg, administered once every 3 weeks (Q3w), via intravenous infusion on Day 1 of each treatment cycle

DRUG

QL1706

Drug: QL1706 Iparomlimab and Tuvonralimab (QL1706) : 5 mg/kg in total, administered once every 3 weeks (Q3w), via intravenous infusion on Day 1 of each treatment cycle

Trial Locations (1)

250000

Qilu Hospital of Shandong University, Ji'an

All Listed Sponsors
lead

Qilu Hospital of Shandong University

OTHER